Jakafi, Jakavi (ruxolitinib) is a small molecule pharmaceutical. Ruxolitinib was first approved as Jakafi on 2011-11-16. It is used to treat polycythemia vera and primary myelofibrosis in the USA. It has been approved in Europe to treat myeloproliferative disorders and polycythemia vera. The pharmaceutical is active against tyrosine-protein kinase JAK2 and tyrosine-protein kinase JAK1. In addition, it is known to target non-receptor tyrosine-protein kinase TYK2, tyrosine-protein kinase JAK3, and proto-oncogene tyrosine-protein kinase Src. Jakafi's patents are valid until 2028-06-12 (FDA).
|Indication||myeloproliferative disorders, polycythemia vera, primary myelofibrosis|
|Drug Class||Tyrosine kinase inhibitors|